Advances in the identification of β-secretase inhibitors
Authors:
- 29 March 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 8 (6) , 709-731
Abstract
Introduction: Alzheimer's disease (AD), which is characterized by progressive intellectual deterioration, is the most common cause of dementia. β-Secretase (or BACE1) expression is a trigger for amyloid β peptide formation, a cause of AD, and thus is a molecular target for the development of drugs against AD. Many BACE1 inhibitors have been identified by academic and pharmaceutical research groups and a number of advanced technologies in drug discovery have been applied to the drug discovery. Areas covered: The purpose of this review is to present and discuss the methodologies used for BACE1 inhibitor drug discovery via substrate- and structure-based design, high-throughput screening and fragment-based drug design. The authors also review the advantages and disadvantages of these methodologies. Expert opinion: Many BACE1 inhibitors have been designed using X-ray crystal structure-based drug design as well as through in silico screening. Nevertheless, there are serious problems with regards to deciding the best X-ray crystal structure for designing BACE1 inhibitors through computational approaches. There are two prominent configurations of BACE1 but there is still room for improvement. Future developments may make it possible to identify BACE1 inhibitors as potential drug candidates.Keywords
This publication has 105 references indexed in Scilit:
- Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer DiseaseJournal of Biological Chemistry, 2012
- β‐Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigmentEMBO Molecular Medicine, 2012
- Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-PeptidesJournal of Medicinal Chemistry, 2012
- The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 proteaseScientific Reports, 2012
- Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based designBioorganic & Medicinal Chemistry Letters, 2012
- BACE1 Inhibitor Peptides: Can an Infinitely Small kcat Value Turn the Substrate of an Enzyme into Its Inhibitor?ACS Medicinal Chemistry Letters, 2011
- β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic miceThe FASEB Journal, 2010
- Novel Huprine Derivatives with Inhibitory Activity toward β‐Amyloid Aggregation and Formation as Disease‐Modifying Anti‐Alzheimer Drug CandidatesChemMedChem, 2010
- Potent memapsin 2 (β-secretase) inhibitors: Design, synthesis, protein-ligand X-ray structure, and in vivo evaluationBioorganic & Medicinal Chemistry Letters, 2008
- A non‐amyloidogenic function of BACE‐2 in the secretory pathwayJournal of Neurochemistry, 2002